A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer
Trial Description: This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.
- Conditions: breast neoplasms
- Phase: I
- Trial ID: NCT02057133
- Protocol ID: 14-070